We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.14% | 35.45 | 35.20 | 35.60 | 35.65 | 35.20 | 35.45 | 246,675 | 16:35:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.14 | 105.85M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/4/2023 17:44 | Plenty of big sells! looking forward to the fundraising! LOL Therefore, from June 2022 it had roughly 13 months of cash runway it's fair to say the end of the cash runway is in sight FOR EVERY BUYER THERE MUST BE A SELLER Jay: What I meant was, where did the shares you purchased come from? They didn’t come out of thin air. Someone had to sell them to you. The market has two types of investors: individuals like you and me, and institutional investors such as pension funds, mutual funds and hedge funds. Do you believe the seller was more likely another individual investor like you? Or was the seller more likely one of those institutional investors? Haden: I would guess the seller was another individual investor. Jay: That’s incorrect. Since today institutional investors do about 90 percent of all trading, there’s about a 90 percent chance the seller was an institution. Since we now agree the underlying reason you bought the stock was that you believed it would outperform the market, we can also agree the underlying reason the institutional investor sold the stock was that it believed the stock would underperform the market. If that were not the case, it would have continued to hold the stock. Correct? Haden: I guess so. Jay: Okay. You believed it would outperform the market, and the institutional investor believed it would underperform. How many of you can be correct? Haden: Just one. Jay: If you’re re being perfectly honest with yourself, who do you believe had more knowledge about the company”you or the institutional investor? Haden: I’d have to say the institutional investor. | lbo | |
18/4/2023 17:33 | Plenty of buying/momentum right up until the close.....looking forward to tomorrow :-) | broomrigg | |
18/4/2023 17:24 | Deja Vu! Over six years later and the ‘very exciting times ahead’ are still ‘we believe’, ‘think’ and ‘hope’ are still ahead! LOL But lets not mention how many big group distributors and products vanished off the face of the planet for Futura over the years! Just like the original Futura FAQS did about it being a placebo! LOL Surely it will be different this this with Leslie from his flat and Eroxon Limited! ROFMLAO | lbo | |
18/4/2023 17:05 | LOL Yes Futura’s estimates are very reliable! Any update on the enforceable patent ‘coming soon’? ‘It was estimated that CSD500 could capture about 6 per cent of the condom branded market, which would mean roughly £35m a year in sales for SSL. Assuming a percentage royalty take for Futura in the late teens, CSD500 could be generating over £6m a year in sales for the group’ And ‘Futura estimated it would receive royalties of £1.7-2.5m per annum per 1% of global market share’ | lbo | |
18/4/2023 16:38 | ...and LiarBO knows all about the failure of CSD500! Before its launch he was singing FUM's praises, he'd clearly bought in big time. But then it failed, LiarBO was forced to sell at the bottom of the market because he'd invested more than he could afford to lose, and that started his 'Six Year War' against FUM. That's the length of time he's been bashing this stock. What an absolute fool and massive loser! If he hadn't made that schoolboy error of investing too much, he could be like the majority of LTHs here who made their money back. How do I know this? If you read back his posts, he was involved in quite a few threads, discussing his various holdings, but suddenly they all stopped at the same time CSD500 failed. He'd obviously switched his money to FUM and lost the lot. Haha! And yet here he is, trying to dissuade any newbies or sniffers not to invest! You'd have to be really, really stupid to take any investment advice from that loser! You don't need to take my advice either because I'm not offering any, apart from the old adage 'if you see a bandwagon passing, you're already too late!' My prediction (and I've been right before) is that after a brief flurry this week, the share price will start to drift down again until the FDA rubber stamps the US approval to market. That'll be the big one! (Take note, Truant! That'll be when to put your imaginary short in!) | petroc | |
18/4/2023 16:11 | LOL Didn’t Walmart and Amazon once sell their Pet500 product! Not for sale anymore!!! Unfortunately that didn't sell ‘huge volumes’ just like CSD500 didn’t! And this Med3000/Eroxon doesn’t even have an enforceable patent and cant even substantiate its even having any effect beyond what an arousal gel would under the same deficient test circumstances! Here's a startling fact: between 80% and 90% of new product launches fail, according to multiple studies including Harvard Business Review. Each year, more than 30,000 new products hit the market, from companies large and small, and year after year, history is littered with dead carcasses Research at the Ehrenberg-Bass Institute shows new product launches can be a risky undertaking for brand owners. Investigating 83,719 new product introductions over an eight-year period, the research finds around one in four new products failed to survive one year after launch. This failure rate increased to around 40% two years after launch. Why Most Product Launches Fail | lbo | |
18/4/2023 16:09 | The Boots tie-up is great news as the likelihood of this instantly hitting the shelves at Walgreens USA once FDA approval received very likely. | amelio | |
18/4/2023 15:52 | In lots of papers of now.hTTps://www.dail | soulected | |
18/4/2023 15:47 | This news has really captured the attention of the investing community today. Huge volumes. The next couple of trading sessions are going to be very interesting. | amelio | |
18/4/2023 15:46 | Great volume today....persistant buying all day. Well done all holders. | broomrigg | |
18/4/2023 15:45 | On Proactive they talk about more launches coming ... | pdt | |
18/4/2023 15:43 | Game-changing erectile dysfunction gel is now on sale hTTps://mol.im/a/119 | soulected | |
18/4/2023 14:44 | FDA approval up next. Q2 2023 a game changer for the future of FUM. The ED market is set to grow to $6B by 2030. What share of the market does Eroxon take once FDA approval granted and the product commercialised in the US? The opportunity is tremendous. | amelio | |
18/4/2023 14:23 | Its all so predictable! LOL Therefore, from June 2022 it had roughly 13 months of cash runway’ it's fair to say the end of the cash runway is in sight ‘Becaus The Berkshire Hathaway CEO went on to say shorting overvalued stocks is also tricky because "people that have overvalued stocks... Are frequently on some scale between promoter and crook. And that's why they get there." He went on to add: "And they also know how to use that very valuation to bootstrap value into the business, because if you have a stock that's selling at 100 that's worth 10, obviously it's to your interest to go out and issue a whole lot of shares. And if you do that, when you get all through, the value can be 50. In fact, there's a lot of chain letter-type stock promotions that are sort of based on the implicit assumption that the management will keep doing that. because if you have a stock that's selling at 100 that's worth 10, obviously it's to your interest to go out and issue a whole lot of shares. And if you do that, when you get all through, the value can be 50. And if they do it once and build it to 50 by issuing a lot of shares at 100 when it's worth 10, now the value is 50 and people say, "Well, these guys are so good at that. Let's pay 200 for it or 300," and then they could do it again and so on" According to Buffett, if you get caught up in one of these stock promotion schemes,"you can run out of money before the promoter runs out of ideas." | lbo | |
18/4/2023 14:23 | Great post Amelio | k8 rhm | |
18/4/2023 14:20 | Yes ‘here we go’! LOL mikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141 Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he says mikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141 Company is massively over valued if you go by 'concrete' results ! mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141 I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections. I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the shares Unfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 ! mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591 "A couple of decent deals and will be back off to the races." Do you have any idea of how long shareholders have been using these words mikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591 As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated. All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day! mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713 why should it be any different this time when you've still got the same useless lot running the show mikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641 I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-life And where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remuneration I just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a kick | lbo | |
18/4/2023 14:19 | Here we go LBO, LBO Here we go Here we go Here we go ! Go on rub some in - just watch how BIG BOY (more apt name now) responds | mikethebike4 | |
18/4/2023 13:23 | put 'help' in the search box and there is a thread that is read by ADVFN moderators. Do not expect too much from them, as they do not like to lose paying members. | joestalin | |
18/4/2023 12:33 | And here is a link to submit complaints to the ASA about UK products claiming ‘clinically proven’ but cannot provide any adequate placebo controlled studies to substantiate those claims! Make a complaint Quickly and easily submit your ad complaint with us online. We check every issue that you report to us in all of the complaints that we receive and take action where we need to. The information you give us helps us to identify problems that need to be addressed in advertising and alerts us to the issues that matter It is the advertisers responsibility to hold evidence for the claims they make, and it is stipulated in the Advertising Codes that evidence must be held by the advertiser prior to making the claim. Advertisers must submit documentary evidence to the ASA to support any claims they make; the ASA will not seek out the evidence to establish the veracity of the claim for you | lbo | |
18/4/2023 12:31 | Here it is on the Boots site; Just bought some shares, should be good newsflow over the next six months. | pdt |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions